SRR1361795
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INFLAMMATORY_RESPONSE+0.475
- IL6_JAK_STAT3_SIGNALING+0.454
- ALLOGRAFT_REJECTION+0.435
- TNFA_SIGNALING_VIA_NFKB+0.430
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.392
- COAGULATION+0.358
- ANGIOGENESIS+0.351
- INTERFERON_GAMMA_RESPONSE+0.350
- KRAS_SIGNALING_DN+0.341
- INTERFERON_ALPHA_RESPONSE+0.331
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.664
- MYC_TARGETS_V2-0.609
- MYC_TARGETS_V1-0.579
- PROTEIN_SECRETION-0.529
- DNA_REPAIR-0.505
- UNFOLDED_PROTEIN_RESPONSE-0.453
- MTORC1_SIGNALING-0.445
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.388
- PEROXISOME-0.346
- ADIPOGENESIS-0.342
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1394297 | GTEX | — | 0.970 |
| 2 | SRR1488285 | GTEX | — | 0.965 |
| 3 | SRR1500800 | GTEX | — | 0.961 |
| 4 | SRR1468141 | GTEX | — | 0.960 |
| 5 | SRR1358561 | GTEX | — | 0.959 |
| 6 | SRR1417070 | GTEX | — | 0.955 |
| 7 | SRR601201 | GTEX | — | 0.955 |
| 8 | SRR655590 | GTEX | — | 0.953 |
| 9 | SRR1368964 | GTEX | — | 0.950 |
| 10 | SRR1375616 | GTEX | — | 0.949 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INFLAMMATORY_RESPONSE | 0.475 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.454 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.435 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.430 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.392 | Inavolisib | — uncovered |
| COAGULATION | 0.358 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.351 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.350 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.341 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.331 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.311 | Inavolisib | — uncovered |
| COMPLEMENT | 0.276 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.257 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.256 | Idelalisib | — uncovered |
| MYOGENESIS | 0.240 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.237 | Inavolisib | — uncovered |
| APOPTOSIS | 0.210 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.161 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.131 | Idelalisib | — uncovered |
| HYPOXIA | 0.129 | Idelalisib | — uncovered |